系统综述与Meta分析:克罗恩病术前暴露于抗肿瘤坏死因子药物与术后并发症风险
该系统综述与Meta分析纳入20项研究共7115例克罗恩病(CD)患者,评估术前抗肿瘤坏死因子(TNF)治疗与腹部手术后30天内并发症的关系。未校正混杂时,术前抗TNF治疗与感染性并发症风险升高相关(未校正OR 1.49,95%CI 1.08-2.06);校正混杂后,与总并发症和感染性并发症风险升高均显著相关(校正OR分别为1.53和2.09)。作者建议推迟择期手术或术后仔细监测这些患者。
要点
- 术前抗TNF治疗是CD患者术后感染性并发症的独立危险因素。
- 校正混杂后,抗TNF与总并发症(校正OR 1.53)和感染性并发症(校正OR 2.09)风险升高相关。
- 高发病率国家总并发症关联显著(校正OR 1.86),低发病率国家不显著(校正OR 0.77)。
核心结论
- 暴露于抗TNF药物是CD患者术后感染性并发症的独立危险因素,尤其在高发病率国家。
- 作者建议推迟择期手术或术后仔细监测这些患者。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase、Cochrane Library、Scopus和国际临床试验注册平台截至2018年9月的文献。
- 纳入20项研究,共7115例因CD接受腹部手术的患者。
主要发现
- 未校正混杂时,术前抗TNF治疗与感染性并发症风险升高相关(未校正OR 1.49;95%CI 1.08-2.06)。
- 校正混杂后,术前抗TNF治疗与总并发症风险升高显著相关(校正OR 1.53;95%CI 1.11-2.09),与感染性并发症风险升高显著相关(校正OR 2.09;95%CI 1.19-3.65)。
- 亚组分析显示,抗TNF与总并发症的关联在高发病率国家显著(校正OR 1.86;95%CI 1.43-2.42),在低发病率国家不显著(校正OR 0.77;95%CI 0.48-1.25)。
临床怎么用
- 作者建议推迟择期手术或术后仔细监测接受术前抗TNF治疗的CD患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Post-operative complications after anti-tumour necrosis agent treatment for Crohn's disease (CD) have been analysed with conflicting results. AIM: To assess the effects of pre-operative anti-tumour necrosis factor (TNF) therapy on post-operative complications within 30 days post-operatively in patients with CD undergoing abdominal surgery. METHODS: Systematic review with meta-analysis was performed on articles found in MEDLINE, Embase, Cochrane Library, Scopus, and the International Clinical Trials Registry Platform until September 2018. RESULTS: Twenty studies (7115 patients) were included. Without confounder adjustment, pre-operative anti-TNF therapy in patients with CD undergoing abdominal surgery was associated with increased rates of infectious complications (unadjusted odds ratio, OR, 1.49; 95% CI, 1.08-2.06). After confounder adjustment, Pre-operative anti-TNF therapy was significantly associated with both increased rates of total and infectious complications (adjusted OR, 1.53 and 2.09; 95% CI, 1.11-2.09 and 1.19-3.65, respectively). After subgroup analyses, the association between anti-TNF agents and total complications was significant in high incidence countries (adjusted OR, 1.86; 95% CI, 1.43-2.42) but not in low incidence countries (adjusted OR, 0.77; 95% CI, 0.48-1.25). CONCLUSIONS: Exposure to anti-TNF agents is an independent risk factor for post-operative infectious complications in patients with CD, especially in countries with a high incidence of Crohn's disease. We suggest postponing elective surgery or carefully monitoring these patients post-operatively.
引用
- Lin YS, Cheng SW, Wang YH, et al. Systematic review with meta-analysis: risk of post-operative complications associated with pre-operative exposure to anti-tumour necrosis factor agents for Crohn's disease. Aliment Pharmacol Ther. 2019. PMID: 30864199. doi:10.1111/apt.15184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。